PLACEMENT<\/strong><\/h2>\n![\"\"](\"http:\/\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-content\/uploads\/sites\/499\/2024\/09\/PLACEMENT.png\")
<\/figure>\n650 patients with planned leg amputations for PAD, vascular disease, diabetes, or acute\/chronic infection will be recruited from ~20 UK NHS sites, including eight lead sites. Cardiff and Vale University Health Board is the lead site, with their Principal Investigator, David Bosanquet, also the Chief Investigator of the trial. The seven other lead sites include Bristol, Swansea, Imperial, Leicester, Newcastle, Hull and Cambridge. Three new sites have also been activated for recruitment in Liverpool, Basildon, and St George\u2019s in London. All active sites have randomised participants, contributing to the current total of 118 randomised participants (as of 5th September 2024) with Bristol and Hull currently the joint highest recruiting sites each with 26 randomised participants. Two other sites in Norfolk and Manchester have had their site initiation visits and are due to be activated shortly, with another site in Bournemouth having their site initiation visit in October. A further six sites in Belfast, Lancashire, Nottingham, Oxford, Glasgow and Derby are in site set-up.<\/p>\n
At the time of their leg amputation surgery, participants will be randomised to either receive a perineural nerve catheter (PNC) or not. A PNC is a thin plastic tube, placed next to the main leg nerve which is cut during amputation surgery. Participants randomised to receive the PNC will have a local anaesthetic infused for the first five days after leg amputation surgery. All participants will receive additional pain-management medications as required. The primary aim of PLACEMENT is to evaluate if the use of a PNC with continuous local anaesthetic infusion, affects the amount of pain participants experience, compared to no PNC. Secondary aims include assessing the effect of PNC use on participant satisfaction of pain management, and recovery at 3 and 6 months, including chronic pain, wound healing, quality of life, time to achieve prosthesis fitting and level of independence.<\/p>\n
“Amputation surgery is not only a life changing experience for patients, it can also be a very painful one, both in the short and long term. How to reduce pain after amputation has been highlighted as a research priority for both patients, carers and clinicians. We hope PLACEMENT can provide robust data to help patients experience less pain after their amputation, so they can recover quicker and better.<\/em>” Mr David Bosanquet, Consultant Vascular Surgeon, PLACEMENT Chief Investigator.<\/p>\nPLACEMENT included an eight-month internal pilot which ended in June 2024 and has been recommended to proceed to full trial. The PLACEMENT team are aiming to publish lessons learned from the internal pilot, along with a protocol paper in the next 12 months. To find out more about PLACEMENT please contact: Dr Grace Young, PLACEMENT-Trial@cardiff.ac.uk<\/a><\/p>\nCLARITY<\/strong><\/h2>\n![\"\"](\"http:\/\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-content\/uploads\/sites\/499\/2024\/09\/CLARITY.png\")
<\/figure>\nThe CLARITY trial began the set-up phase in January 2024 and achieved a significant milestone in August 2024 by securing regulatory approvals. This trial will involve approximately 20 vascular units in NHS trusts across the UK, aiming to recruit 1,239 participants over three years. The recruitment phase is anticipated to begin in November 2024, with eight lead sites spearheading the effort, including the North Bristol NHS Trust, where the Chief Investigator (CI), Mr Christopher Twine, is based. Recruitment will initiate a nine-month internal pilot phase, before progressing to the full trial upon meeting specified criteria.<\/p>\n
Participants diagnosed with a vascular condition in their leg and preparing for an angioplasty (a procedure that widens narrowed or blocked arteries using a balloon or stent) will be invited to volunteer to participate in the trial. Patients are routinely prescribed antithrombotic regimens to reduce the risk of further arterial blockages; however, the optimal treatment is unknown. CLARITY participants will be randomly assigned to receive one of three commonly prescribed antithrombotic regimens: Clopidogrel, Aspirin plus Clopidogrel, and Aspirin plus Rivaroxaban.<\/p>\n
The primary aim is to identify the regimen most clinically effective in preventing complications post-angioplasty while providing the best balance of efficacy and safety. This is anticipated to provide clearer guidance for clinical practice and enhance patient outcomes.<\/p>\n
To achieve this, CLARITY is designed as an adaptive trial incorporating a planned interim analysis to determine if the treatment arm predicted to be the lowest performing is futile (unlikely to achieve the desired clinical outcomes). If deemed futile, the trial will continue with the remaining two arms; otherwise, all three arms will proceed to the final analysis. This adaptive futility analysis efficiently identifies less effective treatments early, focusing resources on more optimal treatments.<\/p>\n
Secondary aims include evaluating the cost-effectiveness of the regimens, led by a dedicated health economics team from Swansea University, and assessing the delivery and effectiveness of trial interventions within real-world healthcare settings. The latter will be done through interviews with participants and healthcare professionals conducted by specialised qualitative researchers at the CTR. The insights gained are anticipated to enhance trial recruitment processes, understand non-adherence to oral blood-thinning medications, and inform future practices, thereby benefiting patients.<\/p>\n
“CLARITY addresses crucial research priorities for people living with peripheral arterial disease. It is one of only a small handful of trials successfully funded in this area, and the amazing progress we have made up to this point is testament to the skills and expertise of the I3 Vascular Disorders group in the CTR.<\/em>” Mr Christopher Twine, Consultant Vascular Surgeon, <\/em>CLARITY Chief Investigator.<\/p>\nTo find out more about CLARITY Trial please contact: Dr Waku Maboshe, CLARITY-Trial@cardiff.ac.uk<\/a><\/p>\nRecommendations for researchers<\/strong><\/h2>\nThe PLACEMENT and CLARITY trials both have patient and public involvement (PPI) advisory groups who continue to work with us throughout the trial lifecycle, including reviewing and co-producing patient-facing documents and helping to prepare study summaries. We also have PPI members who are a central part of the research team and form part of the trial management group. In CLARITY, one member takes blood-thinning tablets for blocked leg arteries and one member has parents who died of blocked leg arteries.\u00a0In PLACEMENT, one member has had two amputations, one with and without a PNC, and our other member lost their father after an amputation. They have helped plan and run the PLACEMENT Feasibility trial<\/a>\u00a0and plan this larger PLACEMENT trial.<\/p>\nThe findings from these trials will be presented at medical conferences, published in free-to-access medical journals, and shared with people who write amputation surgery and PAD guidelines and policies. We will share the trial results via the national press, amputation charities and social media, including the trial websites and LinkedIn pages.<\/p>\n
Four abstracts relating to PLACEMENT and CLARITY are being presented at the upcoming International Clinical Trials Methodology Conference in Edinburgh in October 2024, and the PLACEMENT and CLARITY teams will also be attending The Vascular Societies\u2019 Annual Scientific Meeting in Brighton in November 2024.<\/p>\n
<\/figure>\n650 patients with planned leg amputations for PAD, vascular disease, diabetes, or acute\/chronic infection will be recruited from ~20 UK NHS sites, including eight lead sites. Cardiff and Vale University Health Board is the lead site, with their Principal Investigator, David Bosanquet, also the Chief Investigator of the trial. The seven other lead sites include Bristol, Swansea, Imperial, Leicester, Newcastle, Hull and Cambridge. Three new sites have also been activated for recruitment in Liverpool, Basildon, and St George\u2019s in London. All active sites have randomised participants, contributing to the current total of 118 randomised participants (as of 5th September 2024) with Bristol and Hull currently the joint highest recruiting sites each with 26 randomised participants. Two other sites in Norfolk and Manchester have had their site initiation visits and are due to be activated shortly, with another site in Bournemouth having their site initiation visit in October. A further six sites in Belfast, Lancashire, Nottingham, Oxford, Glasgow and Derby are in site set-up.<\/p>\n
At the time of their leg amputation surgery, participants will be randomised to either receive a perineural nerve catheter (PNC) or not. A PNC is a thin plastic tube, placed next to the main leg nerve which is cut during amputation surgery. Participants randomised to receive the PNC will have a local anaesthetic infused for the first five days after leg amputation surgery. All participants will receive additional pain-management medications as required. The primary aim of PLACEMENT is to evaluate if the use of a PNC with continuous local anaesthetic infusion, affects the amount of pain participants experience, compared to no PNC. Secondary aims include assessing the effect of PNC use on participant satisfaction of pain management, and recovery at 3 and 6 months, including chronic pain, wound healing, quality of life, time to achieve prosthesis fitting and level of independence.<\/p>\n
“Amputation surgery is not only a life changing experience for patients, it can also be a very painful one, both in the short and long term. How to reduce pain after amputation has been highlighted as a research priority for both patients, carers and clinicians. We hope PLACEMENT can provide robust data to help patients experience less pain after their amputation, so they can recover quicker and better.<\/em>” Mr David Bosanquet, Consultant Vascular Surgeon, PLACEMENT Chief Investigator.<\/p>\n PLACEMENT included an eight-month internal pilot which ended in June 2024 and has been recommended to proceed to full trial. The PLACEMENT team are aiming to publish lessons learned from the internal pilot, along with a protocol paper in the next 12 months. To find out more about PLACEMENT please contact: Dr Grace Young, PLACEMENT-Trial@cardiff.ac.uk<\/a><\/p>\n The CLARITY trial began the set-up phase in January 2024 and achieved a significant milestone in August 2024 by securing regulatory approvals. This trial will involve approximately 20 vascular units in NHS trusts across the UK, aiming to recruit 1,239 participants over three years. The recruitment phase is anticipated to begin in November 2024, with eight lead sites spearheading the effort, including the North Bristol NHS Trust, where the Chief Investigator (CI), Mr Christopher Twine, is based. Recruitment will initiate a nine-month internal pilot phase, before progressing to the full trial upon meeting specified criteria.<\/p>\n Participants diagnosed with a vascular condition in their leg and preparing for an angioplasty (a procedure that widens narrowed or blocked arteries using a balloon or stent) will be invited to volunteer to participate in the trial. Patients are routinely prescribed antithrombotic regimens to reduce the risk of further arterial blockages; however, the optimal treatment is unknown. CLARITY participants will be randomly assigned to receive one of three commonly prescribed antithrombotic regimens: Clopidogrel, Aspirin plus Clopidogrel, and Aspirin plus Rivaroxaban.<\/p>\n The primary aim is to identify the regimen most clinically effective in preventing complications post-angioplasty while providing the best balance of efficacy and safety. This is anticipated to provide clearer guidance for clinical practice and enhance patient outcomes.<\/p>\n To achieve this, CLARITY is designed as an adaptive trial incorporating a planned interim analysis to determine if the treatment arm predicted to be the lowest performing is futile (unlikely to achieve the desired clinical outcomes). If deemed futile, the trial will continue with the remaining two arms; otherwise, all three arms will proceed to the final analysis. This adaptive futility analysis efficiently identifies less effective treatments early, focusing resources on more optimal treatments.<\/p>\n Secondary aims include evaluating the cost-effectiveness of the regimens, led by a dedicated health economics team from Swansea University, and assessing the delivery and effectiveness of trial interventions within real-world healthcare settings. The latter will be done through interviews with participants and healthcare professionals conducted by specialised qualitative researchers at the CTR. The insights gained are anticipated to enhance trial recruitment processes, understand non-adherence to oral blood-thinning medications, and inform future practices, thereby benefiting patients.<\/p>\n “CLARITY addresses crucial research priorities for people living with peripheral arterial disease. It is one of only a small handful of trials successfully funded in this area, and the amazing progress we have made up to this point is testament to the skills and expertise of the I3 Vascular Disorders group in the CTR.<\/em>” Mr Christopher Twine, Consultant Vascular Surgeon, <\/em>CLARITY Chief Investigator.<\/p>\n To find out more about CLARITY Trial please contact: Dr Waku Maboshe, CLARITY-Trial@cardiff.ac.uk<\/a><\/p>\n The PLACEMENT and CLARITY trials both have patient and public involvement (PPI) advisory groups who continue to work with us throughout the trial lifecycle, including reviewing and co-producing patient-facing documents and helping to prepare study summaries. We also have PPI members who are a central part of the research team and form part of the trial management group. In CLARITY, one member takes blood-thinning tablets for blocked leg arteries and one member has parents who died of blocked leg arteries.\u00a0In PLACEMENT, one member has had two amputations, one with and without a PNC, and our other member lost their father after an amputation. They have helped plan and run the PLACEMENT Feasibility trial<\/a>\u00a0and plan this larger PLACEMENT trial.<\/p>\n The findings from these trials will be presented at medical conferences, published in free-to-access medical journals, and shared with people who write amputation surgery and PAD guidelines and policies. We will share the trial results via the national press, amputation charities and social media, including the trial websites and LinkedIn pages.<\/p>\n Four abstracts relating to PLACEMENT and CLARITY are being presented at the upcoming International Clinical Trials Methodology Conference in Edinburgh in October 2024, and the PLACEMENT and CLARITY teams will also be attending The Vascular Societies\u2019 Annual Scientific Meeting in Brighton in November 2024.<\/p>\nCLARITY<\/strong><\/h2>\n
<\/figure>\nRecommendations for researchers<\/strong><\/h2>\n